Immunotherapy Drugs Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global immunotherapy drugs market size was estimated at USD 101,899.8 million in 2023 and is projected to reach USD 284,533.4 million in 2030 at a CAGR of 15.8 % during the forecast period 2024-2030.

Immunotherapy drugs are a class of treatments designed to enhance or suppress the body’s immune system to fight diseases, particularly cancer. Unlike traditional therapies such as chemotherapy or radiation, which target the disease directly, immunotherapy works by stimulating the body’s immune system to recognize and attack cancer cells, or by blocking mechanisms that allow tumours to evade immune responses. This category includes checkpoint inhibitors, monoclonal antibodies, cancer vaccines, and immune cell therapy, all of which have been pivotal in treating various types of cancers, such as melanoma, lung cancer, and lymphoma. The increasing adoption of these therapies has transformed cancer treatment paradigms, leading to significant advancements in oncology.

The scope of the immunotherapy drugs market is vast, encompassing a wide range of therapeutic areas, including oncology, autoimmune disorders, infectious diseases, and more. While oncology remains the dominant segment, growing interest in autoimmune conditions, such as rheumatoid arthritis and psoriasis, is contributing to the expansion of the market. The global market for immunotherapy drugs is expected to continue growing as more therapies receive regulatory approval, and ongoing research aims to discover new targets and improve the efficacy and safety of existing treatments. In addition, the increasing prevalence of cancer and autoimmune diseases across the world provides a substantial market opportunity for these therapies, which are becoming a critical part of treatment regimens for a variety of conditions.

Several key trends are shaping the immunotherapy drugs market. Personalized medicine is one of the most prominent trends, where treatments are tailored to an individual’s genetic makeup and the specific characteristics of their disease. Advances in genomics, biomarker research, and diagnostic tools are facilitating this shift toward precision oncology. Another significant trend is the increasing use of combination therapies, which combine immunotherapies with other treatment modalities like chemotherapy, radiation, or targeted therapies. This approach aims to improve patient outcomes by leveraging the complementary effects of multiple therapeutic strategies. Additionally, there is a growing focus on developing immunotherapies for cancers that are traditionally considered difficult to treat, such as pancreatic cancer and glioblastoma.

The drivers of the immunotherapy drugs market are largely driven by the growing burden of cancer and other chronic diseases, alongside significant advances in research and clinical trials. The success of blockbuster drugs like Keytruda, Opdivo, and Kymriah has created a strong market momentum, encouraging continued investment from both pharmaceutical companies and research institutions. Regulatory support from agencies like the FDA, which have been accelerating the approval process for immunotherapies, also plays a key role in market growth. Furthermore, technological innovations in biomanufacturing, as well as increased funding for immuno-oncology research, are helping to lower production costs and improve drug accessibility. Rising healthcare expenditures and the demand for more effective and less toxic treatments are also driving the widespread adoption of immunotherapies across global markets.

Delvens Industry Expert's Standpoint

Experts in the Immunotherapy Drugs Market highlight several key trends driving growth and innovation. The immunotherapy drugs market is rapidly expanding, driven by the increasing prevalence of cancer and autoimmune diseases, along with advancements in personalized medicine and combination therapies. Immunotherapies, including checkpoint inhibitors and monoclonal antibodies, are revolutionizing cancer treatment by boosting the body's immune response against tumours. The market is supported by strong research and regulatory approval, with key trends focusing on precision treatments and the development of therapies for hard-to-treat cancers. Ongoing innovations in drug production and growing investment in immuno-oncology are fuelling further market growth, making these therapies an integral part of modern medical care.

Market Portfolio

Key Findings

• The immunotherapy drugs market is segmented by type into antibody drugs, inhibitor drugs, interferons & interleukins, cancer vaccines, and other immunotherapies such as oncolytic virus therapy and T-cell therapy. In 2023, antibody drugs dominate the market share. The growth of this market is primarily driven by the increasing incidence of cancer, the expanding use of biological therapies, higher investments in research and development by both governments and immunotherapy companies, and supportive government policies.

• The immunotherapy drugs market is categorized by application into cancer, autoimmune and inflammatory diseases, haematology, osteology, neurology, and other areas such as ophthalmology, dermatology, and cardiovascular diseases. In 2023, cancer accounted for the largest market share, driven by the anticipated rise in global cancer cases, a growing number of product approvals for cancer treatments, and increased investment in research and development.

• Based on the route of administration, the immunotherapy drugs market is primarily divided into intravenous, subcutaneous, and other routes such as intravitreal and intramuscular. In 2023, the intravenous route held the largest share of the market and is expected to experience the highest compound annual growth rate (CAGR) during the forecast period. This dominance and rapid growth are driven by the increasing preference for intravenous administration, which allows for direct delivery into the bloodstream, ensuring faster and more consistent therapeutic effects for conditions like cancer and autoimmune diseases.

• Based on end users, the immunotherapy drugs market is broadly categorized into hospitals, long-term care facilities, and other end users, such as specialty care centres. In 2023, the hospitals segment held the largest share of the market. Hospitals are major consumers of monoclonal antibodies (mAbs) due to their targeted therapeutic properties, rapid diagnostic capabilities, and effectiveness in treating a range of diseases, including cancer, autoimmune disorders, and infectious diseases.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America region is projected to hold the largest market share. Factors such as rising cancer incidence, advancements in immunotherapy, growing adoption of biological therapies, increased R&D investment, regulatory approvals, favourable government policies, improved healthcare infrastructure, rising awareness and acceptance, expansion of clinical applications, enhanced therapeutic outcomes have triggered the immunotherapy drugs market in the region.

Regional Analysis

North America to Dominate the Market

• North America led the global immunotherapy drugs market in 2021, capturing over 44.90% of the total revenue. The region's growth is expected to continue, driven by the approval and launch of new immunotherapy treatments and favourable reimbursement policies. For example, in October 2021, Merck’s Keytruda, an anti-PD-1 therapy, received FDA approval in combination with chemotherapy for cervical cancer. Additionally, in August 2021, Bristol Myers Squibb's OPDIVO (nivolumab) was approved by the FDA for treating urothelial carcinoma.

Competitive Landscape

• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• F. Hoffman-La Roche Ltd.
• Pfizer Inc.
• AstraZeneca
• Novartis AG
• Amgen Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Sanofi
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd
• GSK PLC
• AbbVie Inc. ImmunoCore Holdings PLC
• Astellas Pharma Inc.
• Genmab A/S
• Macrogenics, Inc.
• Ferring BV
• Y-Mabs Therapeutics, Inc.
• Biogen
• Kyowa Kirin Co., Ltd.
• Swedish Orphan Biovitrum AB
• Boehringer Ingelheim International GmbH

Recent Developments

• In May 2024, Merck made a strategic move by acquiring EyeBio, a UK-based biotechnology firm focused on ophthalmology. As part of the acquisition, Merck gained rights to EyeBio’s investigational candidate, Restoret (EYE103), a tri-specific antibody designed to act as an agonist of the WNT signaling pathway. This innovative therapy has the potential to impact the treatment of eye diseases, broadening Merck's portfolio beyond oncology and into ophthalmology, further enhancing its position in the biopharmaceutical market.

• In December 2023, F. Hoffmann-La Roche expanded its therapeutic capabilities in gastrointestinal health through the acquisition of Telavant Holdings, Inc., a company jointly owned by Roivant Sciences and Pfizer. This acquisition aims to strengthen Roche’s portfolio by advancing the development of innovative therapies targeting gastrointestinal disorders. By integrating Telavant's pipeline, Roche is positioning itself to play a critical role in addressing unmet medical needs in gastrointestinal healthcare, aligning with its broader strategic focus on expanding its presence in specialty medicine.

• In May 2023, Janssen Global Services, a subsidiary of Johnson & Johnson, entered into a collaboration with Cellular Biomedicine Group Inc. (CBMG) to advance chimeric antigen receptor (CAR) T-cell therapies. This partnership is focused on developing and commercializing CAR T-cell therapies for B-cell malignancies, a class of blood cancers. By leveraging CBMG’s expertise in cell therapy and Janssen's resources in oncology, the collaboration aims to enhance the efficacy and accessibility of CAR T-cell treatments, marking a significant step in the evolution of immunotherapy-based cancer treatments.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
• Gain authentic and granular data access for the Immunotherapy Drugs Market to understand the trends and the factors involved in changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope